Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2

Main Article Content

Ruth Ann Vleugels
Brigham and Women's Hospital, Boston, USA

Bianca Maria Piraccini
Private Dermatology Practice, Bologna, Italy

Natasha Mesinkovska
University of California, Irvine, USA

Arash Mostaghimi
Harvard Medical School, Boston, USA

Yutaka Shimomura
Yamaguchi University, Yamaguchi, Japan

Angelina Sontag
Eli Lilly and Company, Indianapolis, USA

Fionn McSwiney
Eli Lilly and Company, Indianapolis, USA

Hitendra Pandey
Eli Lilly and Company, Indianapolis, USA

Karen Denning
Eli Lilly and Company, Indianapolis, USA

Brett King
Dermatology Physicians of Connecticut, Fairfield, USA

Keywords

Alopecia Areata

References

1. King B, et al. J Am Acad Dermatol. 2021;85:847-853.

2. Lintzeri DA, et al. J Dtsch Dermatol Ges. 2022;20:59-90.

3. King B, et al. N Engl J Med. 2022;386:1687-1699.

4. Senna M, et al. J Eur Acad Dermatol Venereol. 2024;38:583-593.

5. King B, et al. Am J Clin Dermatol. 2025;26:611-622.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/t6v95c18

Article Details

How to Cite
1.
Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2. J of Skin. 2025;9(6):s662. doi:10.25251/t6v95c18
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>